Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV
Tweet Send to a Friend
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
